Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Race Oncology Ltd. ( (AU:RAC) ) has shared an announcement.
Race Oncology Ltd has announced the activation of its first clinical trial site in Hong Kong at Queen Mary Hospital for the Phase 1 trial of RC220 in advanced solid tumours. This trial aims to assess the safety, tolerability, and pharmacokinetics of RC220 in combination with doxorubicin, with the goal of determining the maximum tolerated dose. The trial’s expansion into Hong Kong and South Korea is expected to accelerate patient recruitment and provide valuable data on RC220’s efficacy and safety in the East Asian market, which is crucial for the company’s strategic growth and market positioning.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, bisantrene, is a small molecule anticancer drug known for its therapeutic benefits and reduced cardiotoxicity compared to anthracyclines like doxorubicin.
Average Trading Volume: 93,281
Technical Sentiment Signal: Sell
Current Market Cap: A$207.6M
Learn more about RAC stock on TipRanks’ Stock Analysis page.